Alnylam Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript
All right. Thank you, everyone, for coming today. This is to the TD Cowen Healthcare Conference and the fireside chat for Alnylam Pharmaceuticals. I am the covering analyst Ritu Baral. And with us from Alnylam, we have Kevin Fitzgerald, CSO; and Jeff Poulton, Chief Financial Officer.
Questions & Answers
So guys, welcome. Thank you for being here. Let's start with AMVUTTRA. That's where every conversation of mine starts. And the revenue growth driver, sustainability of growth specifically, how are you guys describing the key drivers behind AMVUTTRA recent revenue growth? And how sustainable is this trajectory not just through 2026, but beyond.
Yeah. Thanks for the question. I'd say there's probably two or three fundamental things that underpin our confidence in the growth going forward. One is just the growth of the category
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
